Quantbot Technologies LP Buys 61,211 Shares of Qiagen (NYSE:QGEN)

Quantbot Technologies LP boosted its position in Qiagen (NYSE:QGEN) by 536.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,611 shares of the company’s stock after acquiring an additional 61,211 shares during the quarter. Quantbot Technologies LP’s holdings in Qiagen were worth $3,309,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in QGEN. Massmutual Trust Co. FSB ADV increased its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the last quarter. CWM LLC grew its position in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares during the last quarter. Atria Investments Inc grew its position in Qiagen by 6.0% during the third quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock valued at $348,000 after acquiring an additional 433 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of Qiagen by 8.0% during the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock worth $285,000 after acquiring an additional 461 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after acquiring an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of Qiagen stock opened at $43.76 on Thursday. The business has a 50 day moving average of $43.32 and a 200 day moving average of $43.73. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The company has a market cap of $9.99 billion, a PE ratio of 112.21, a P/E/G ratio of 3.35 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Robert W. Baird lifted their target price on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.